Results 1 to 4 of 4

Thread: Mutant Covid Pill Coming

  1. #1
    So if the Son sets you free, you will be free indeed. John's Avatar
    Join Date
    Jul 2015
    Posts
    7,824
    Thanked: 7519

    Mutant Covid Pill Coming

    Merck's new COVID-19 pill, known as molnupiravir, headed for FDA review for emergency authorization, could potentially carry serious safety issues stemming from the method used to kill the virus, scientists warned, according to a report.

    The oral antiviral medication integrates into the genetic makeup of the virus, causing a large number of mutations to destroy the virus. However, some laboratory tests indicated the drug's ability to cause mutations in genetic material of mammalian cells, theoretically causing cancer or birth defects, Barron's reported.

    However, a Merck spokesperson told Fox News that tests in animals indicate otherwise: "The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems," a statement reads in part.
    Merck's COVID-19 pill could carry serious safety concerns, scientists warn

    Give me horse paste!

    Merck also makes Ivermectin, but nooooo.

  2. The Following User Says Thank You to John For This Useful Post:

    Highly Favoured (01-07-2022)

  3. #2
    So if the Son sets you free, you will be free indeed. John's Avatar
    Join Date
    Jul 2015
    Posts
    7,824
    Thanked: 7519
    Another feature of the pill - Not unlike the "vaccine", It doesn't work.

    NEW DELHI, Oct 8 (Reuters) - Merck & Co's (MRK.N) experimental antiviral drug molnupiravir has not shown "significant efficacy" against moderate COVID-19, a source with the Drug Controller General of India said.

    Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate COVID-19 patients, the regulator's expert committee said on Friday. read more

    "There is no significant efficacy against moderate COVID and the effective efficacy is towards mild cases," the source said on condition of anonymity due to the sensitive nature of the discussions.

    The regulator and health ministry did not immediately respond to a request seeking comment.
    Merck drug less effective against moderate COVID -India regulatory source | Reuters

  4. #3
    Senior Member Romans828's Avatar
    Join Date
    Jul 2015
    Location
    7th Heaven
    Posts
    3,642
    Thanked: 3221

  5. #4
    So if the Son sets you free, you will be free indeed. John's Avatar
    Join Date
    Jul 2015
    Posts
    7,824
    Thanked: 7519
    India Won't Add Merck's COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns


    India's top health research body announced on Wednesday that it won't be adding Merck's COVID-19 antiviral pill molnupiravir to its national treatment protocol, citing concerns over its safety.

    The state-run Indian Council of Medical Research (ICMR) said it had become aware of "major safety concerns" that prompted the decision, despite India's drug regulator in December approving the drug for emergency use.

    It comes after France in December also canceled its order for the drug, developed by Merck and Ridgeback Biotherapeutics, following disappointing trial data suggesting its drug was markedly less effective than previously thought.

    "Molnupiravir has major safety concerns including teratogenicity, mutagenicity, muscle and bone damage. If this drug is given, contraception must be done for three months as the child may have problems," ICMR Director-General Balram Bhargava told local media on Wednesday.

    Bhargava noted that the United States Food and Drug Administration (FDA) issued an emergency use authorization for Merck's COVID-19 pill based on 1,433 patients with a 3 percent reduction in moderate disease when given in mild cases.

    Members of the FDA's Antimicrobial Drugs Advisory Committee in November voted 13 for and 10 against the emergency use authorization for molnupiravir, agreeing with the idea that the drug's benefits outweigh its potential risks, including concerns about potential birth defects.

    However, "we must remember that this drug has major safety concerns," Bhargava said, adding that the drug causes teratogenicity, or the ability to cause defects in a developing fetus, mutagenicity, or permanent transmissible changes in the structure of genetic material of cells, cartilage damage, and can also be damaging to muscles.

    Moreover, Bhargava said contraception would also have to be given to individuals who take the drug—regardless of whether they are male or female— because "the child born could be problematic with teratogenic influences."

    "The WHO has not included it, the UK has not included it as of now. As of now, the current recommendation stands that it is not part of the national taskforce treatment," Bhargava said.

    However, Bhargava said that experts will continue to discuss the potential use of the treatment in the country, where virus case numbers are currently surging.
    India Won't Add Merck's COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns

Tags for this Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  
Has your Toyota Prius warranty expired? Get a fast online quote from CarWarrantyUS today. Enjoy the open road and leave the repairs to us.